Some people feel a boost in energy within hours, while for others, it builds gradually over a few days
Beyond T2D and weight management in individuals with overweight or obesity, GLP-1 receptor agonists are approved for metabolic dysfunction associated steatohepatitis in people with moderate or advanced fibrosis, obstructive sleep apnea in obese adults, reduction of major adverse cardiovascular events in adults with T2D and cardiovascular disease (CVD), and slowing progression of chronic kidney disease and cardiovascular mortality in adults with both chronic kidney disease and T2D
A practical question in clinical practice: if a patient takes a PPI daily, should they stop it before starting Rybelsus
So why, after forming new eating habits and shrinking their stomachs, do pts tend to regain weight after d/c these meds
Understanding the reasons behind denials and knowing how to appeal can improve your chances